LNTH News and Press, Lantheus Holdings Inc. From 11/07/19

Lantheus’ Value-Creating Vision for Integrating and Executing Transaction is Best Path Forward for Progenics Lantheus’ In-Place Infrastructure and Commercial Capabilities Will Ensure the Progress of AZEDRA, and the PyL and 1095 Programs Lantheus Holdings, Inc. ( ...

Progenics Pharmaceuticals ( PGNX +4.9% ) is sending a letter to shareholders urging them to revoke any consents they may have submitted to activist investor Velan Capital LP and to defer sending Velan any consents until they have the opportunity to read the preliminary S-4 detailing the ...

Image source: The Motley Fool. Lantheus Holdings Inc   (NASDAQ: LNTH) Q3 2019 Earnings Call Oct 31, 2019 , 8:00 a.m. ET Operator Continue reading

Lantheus Holding Inc. (LNTH) Q3 2019 Earnings Conference Call October 31, 2019, 08:00 AM ET Company Participants Mark Kinarney - Director, IR Relations Mary Anne Heino - President & CEO Robert Marshall - CFO & Treasurer Conference Call Participants Larry Solow - CJS...

Lantheus (NASDAQ: LNTH ): Q3 Non-GAAP EPS of $0.28 beats by $0.07 ; GAAP EPS of $0.12 misses by $0.08 . More news on: Lantheus Holdings, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Worldwide revenue of $85.8 million for the third quarter 2019, representing a decrease of 3.5% from the prior year period ($88.9 million, which includes $7.5 million of opportunistic TechneLite® sales to ANSTO) Net income of $4.9 million for the third quarter 2019, representing a ...

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced Mar...

ISS Recognizes that Shareholders Should Have Full Information About the Lantheus Transaction Before Making Significant Decisions About the Company Progenics Urges Shareholders to Protect the Value of Their Investment by Revoking Consent to ALL of Velan’s Proposals NEW YOR...

Flags Velan’s Knowledge of Lantheus Transaction Weeks Before It Was Made Public Raises Significant Concerns About Velan’s Questionable Securities Trading, Governance and Ethical Practices Asks Velan’s Nominees if They Want to Be Associated with These Questionab...

On October 2nd, Lantheus Holdings ( LNTH ) Progenics Pharmaceuticals ( PGNX ), announced an agreement for Lantheus to acquire Progenics in an all-stock transaction. According to the press release, "the transaction has been unanimously approved by the Boards of Directors of both companies." U...